3SBio Inc (83B) - Net Assets
Based on the latest financial reports, 3SBio Inc (83B) has net assets worth €18.94 Billion EUR (≈ $22.15 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€23.83 Billion ≈ $27.86 Billion USD) and total liabilities (€4.89 Billion ≈ $5.71 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 3SBio Inc (83B) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.94 Billion |
| % of Total Assets | 79.49% |
| Annual Growth Rate | 13.04% |
| 5-Year Change | 37.75% |
| 10-Year Change | N/A |
| Growth Volatility | 6.28 |
3SBio Inc - Net Assets Trend (2016–2024)
This chart illustrates how 3SBio Inc's net assets have evolved over time, based on quarterly financial data. Also explore 83B total assets for the complete picture of this company's asset base.
Annual Net Assets for 3SBio Inc (2016–2024)
The table below shows the annual net assets of 3SBio Inc from 2016 to 2024. For live valuation and market cap data, see 3SBio Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €18.04 Billion ≈ $21.09 Billion |
+9.22% |
| 2023-12-31 | €16.51 Billion ≈ $19.31 Billion |
+7.23% |
| 2022-12-31 | €15.40 Billion ≈ $18.00 Billion |
+5.07% |
| 2021-12-31 | €14.66 Billion ≈ $17.14 Billion |
+11.95% |
| 2020-12-31 | €13.09 Billion ≈ $15.31 Billion |
+26.39% |
| 2019-12-31 | €10.36 Billion ≈ $12.11 Billion |
+16.30% |
| 2018-12-31 | €8.91 Billion ≈ $10.41 Billion |
+16.75% |
| 2017-12-31 | €7.63 Billion ≈ $8.92 Billion |
+12.76% |
| 2016-12-31 | €6.77 Billion ≈ $7.91 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to 3SBio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 493.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €10.78 Billion | 69.83% |
| Other Components | €4.66 Billion | 30.17% |
| Total Equity | €15.44 Billion | 100.00% |
3SBio Inc Competitors by Market Cap
The table below lists competitors of 3SBio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lien Viet Post Joint Stock Commercial Bank
VN:LPB
|
$5.88 Billion |
|
Pharmaron Beijing Co Ltd
SHE:300759
|
$5.88 Billion |
|
Reece Ltd
AU:REH
|
$5.88 Billion |
|
Sandfire Resources Ltd
AU:SFR
|
$5.89 Billion |
|
E Ink Holdings
TWO:8069
|
$5.87 Billion |
|
Zhejiang CFMoto Power Co Ltd
SHG:603129
|
$5.87 Billion |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
$5.87 Billion |
|
Bank of Ayudhya Public Company Limited
F:NVAU
|
$5.87 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 3SBio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,033,771,000 to 15,436,258,000, a change of 1,402,487,000 (10.0%).
- Net income of 2,090,320,000 contributed positively to equity growth.
- Dividend payments of 555,088,000 reduced retained earnings.
- Share repurchases of 242,448,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.09 Billion | +13.54% |
| Dividends Paid | €555.09 Million | -3.6% |
| Share Repurchases | €242.45 Million | -1.57% |
| Other Changes | €109.70 Million | +0.71% |
| Total Change | €- | 9.99% |
Book Value vs Market Value Analysis
This analysis compares 3SBio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.36x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.82x to 0.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.91 | €2.39 | x |
| 2018-12-31 | €3.39 | €2.39 | x |
| 2019-12-31 | €3.79 | €2.39 | x |
| 2020-12-31 | €4.20 | €2.39 | x |
| 2021-12-31 | €4.85 | €2.39 | x |
| 2022-12-31 | €5.32 | €2.39 | x |
| 2023-12-31 | €5.85 | €2.39 | x |
| 2024-12-31 | €6.55 | €2.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 3SBio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.54%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.95%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.57x
- Recent ROE (13.54%) is above the historical average (12.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 10.92% | 25.47% | 0.25x | 1.69x | €60.31 Million |
| 2017 | 12.65% | 25.05% | 0.27x | 1.86x | €195.71 Million |
| 2018 | 14.83% | 27.86% | 0.33x | 1.61x | €415.72 Million |
| 2019 | 10.12% | 18.31% | 0.36x | 1.54x | €11.21 Million |
| 2020 | 7.82% | 14.96% | 0.32x | 1.65x | €-233.14 Million |
| 2021 | 13.50% | 25.87% | 0.33x | 1.57x | €428.50 Million |
| 2022 | 14.77% | 27.92% | 0.31x | 1.70x | €618.62 Million |
| 2023 | 11.04% | 19.82% | 0.33x | 1.68x | €145.86 Million |
| 2024 | 13.54% | 22.95% | 0.38x | 1.57x | €546.69 Million |
Industry Comparison
This section compares 3SBio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,746,827,785
- Average return on equity (ROE) among peers: -48.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 3SBio Inc (83B) | €18.94 Billion | 10.92% | 0.26x | $5.88 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $-303.75 Million | 0.00% | 0.00x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $2.05 Billion |
| BioNTech SE (22UA) | $20.06 Billion | 47.04% | 0.16x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $3.43 Billion | -0.21% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.83 Billion | 9.08% | 0.22x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.30 Million | 0.00% | 0.00x | $3.31 Million |
About 3SBio Inc
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER… Read more